Pfizer (PFE) Releases Financial Results for Q2 2025

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the company released its financial results for Q2 2025 and reaffirmed the 2025 revenue guidance, while increasing the guidance for adjusted diluted EPS. Pfizer Inc. (NYSE:PFE)’s strong Q2 2025 revenue and EPS performance exhibit its continued emphasis on commercial execution and operational efficiency.

Pfizer (PFE) Releases Financial Results for Q2 2025

A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.

Pfizer Inc. (NYSE:PFE)’s Q2 2025 revenues came in at $14.7 billion, reflecting an increase of $1.4 billion, or 10%, as compared to the prior-year quarter, demonstrating an operational increase of $1.3 billion, or 10%, and a favorable impact of foreign exchange of $22 million. The operational increase was mainly because of an increase in revenues for the Vyndaqel family, Comirnaty, Paxlovid, Padcev, Eliquis, and several other products throughout categories, despite the unfavorable impact of increased manufacturer discounts due to the Inflation Reduction Act (IRA) Medicare Part D Redesign.

Pfizer Inc. (NYSE:PFE) raised FY 2025 adjusted diluted EPS guidance by $0.10 at the midpoint to the range of $2.90 to $3.10. For the same period, the company expects revenues in the range of $61.0 billion – $64.0 billion.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.